Human neoplasms may express and release into the circulation a variety of substances collectively referred to as tumour markers. Serological analysis of these markers has been used in assessing the extent of disease and in monitoring the response to therapy. There are, however, contradicting views regarding the usefulness of blood carcinoembryonic antigen (CEA) in monitoring the clinical course of the breast cancer. It is generally accepted that an increase or decrease of CEA level may reflect the status of disease progression or regression, respectively. Nevertheless, recent literature discourages the use of the CEA assay with the contention that it does not lead to more effective treatment, and that changes in CEA levels are too inconsistent to be used in clinical practice. This review considers the use of CEA measurements in the management of breast cancer and concludes that sufficient data does exist to support its measurement in clinical practice. Of the many potential uses, the major role of CEA measurements in the breast cancer is the follow-up of patients with advanced disease, especially patients with the bone and the liver metastases.